Skip Navigation
Skip to contents



14 results

Paclitaxel and Cisplatin Combination Chemotherapy in Pretreated Breast Cancer

Sohn JH, Kim YT, Rha SY, Yoo NC, Roh JK, Kim BS, Suh CO, Kim GE, Jang WI, Chung HC

  • Cancer Res Treat.
  • 2003 Jun;35(3):267-273.
PURPOSE: A single institute trial of combination chemotherapy, with paclitaxel and cisplatin, in patients with metastatic breast cancer, having failed previous combination chemotherapy, was performed. MATERIALS AND METHODS: Patients were...
Docetaxel and Cisplatin Combination Chemotherapy in Patients with Squamous Cell Carcinomas of the Head and Neck

Lee JH, Lee KW, Choi YJ, Choi JH, Shin HJ, Chung JS, Cho GJ, Lee BJ, Wang SG

  • Cancer Res Treat.
  • 2003 Jun;35(3):261-266.
PURPOSE: The objective of this phase II study was to assess the clinical antitumor activity and toxicities of docetaxel and cisplatin chemotherapy, in patients with locally advanced and metastatic, recurrent...
Detection of p16(INK4A) in the Mixed Cell Populations of Normal Peripheral Blood Mononuclear Cells and Cervical Cancer Cell Lines

Kwon JY, Jo YS, Choi YH, Chang JG, Ryu KS, Rha JG, Han KT

  • Cancer Res Treat.
  • 2003 Jun;35(3):254-260.
PURPOSE: Human papilloma viruses (HPVs) play a central role in the pathogenesis of neoplastic lesions of the uterine cervix. The viral oncoprotein HPV E6 degrades the p53 protein, and the...
Clinical Features of Pulmonary Large Cell Neuroendocrine Carcinoma

Park MS, Kim KD, Chung JH, Shin DH, Chung KY, Kim JH, Lee CY, Kim YS, Kim HJ, Kim SK, Ahn CM, Kim SK, Chang J

  • Cancer Res Treat.
  • 2003 Jun;35(3):245-253.
PURPOSE: This study was performed to investigate the clinical features of large cell neuroendocrine carcinomas (LCNEC). MATERIALS AND METHODS: We retrospectively reviewed the histopathology and clinical information of 37 patients...
A Phase II Study of Paclitaxel and Cisplatin Combination Chemotherapy in Advanced Non-small-cell Lung Cancer

Lee JA, Lee KS, Ahn JS, Byun JH, Song HH, Zang DY, Park YI, Park YS, Mo EK, Kim DK, Lee MG, Hyun IG, Jung KS, Bang SM, Park GY, Park JW, Cho EK, Jeong SH, Shin DB, Lee JH

  • Cancer Res Treat.
  • 2003 Jun;35(3):239-244.
PURPOSE: Paclitaxel and cisplatin, active drugs in the treatment of non-small-cell lung cancer (NSCLC), have been found to be synergistic and less myelotoxic in combination when the paclitaxel is given...
FDG-PET in Mediastinal Nodal Staging of Non-small Cell Lung Cancer: Correlation of False Results with Histopathologic Finding

Baek HJ, Chung JH, Park JH, Zo JI, Cheon GJ, Choi CW, Lim SM, Choi SY, Hong JM, Hong JS

  • Cancer Res Treat.
  • 2003 Jun;35(3):232-238.
PURPOSE: Mediastinal staging of non-small cell lung cancer can be markedly improved by FDG-PET scan, but the problem of false staging of mediastinal nodes by PET scan in non-small cell...
Clinical Pharmacokinetics of Tegafur Administered with Epirubicin and Cisplatin in Patients with Advanced Gastric Cancer

Kang JH, Kim YL, Cho HK, Lee ES, Cha SJ, Hong YS, Lee KS, Kuh HJ

  • Cancer Res Treat.
  • 2003 Jun;35(3):224-231.
PURPOSE: Tegafur, an oral prodrug of 5-fluorouracil (5-FU), has been used in the treatment of gastric cancers. UFT (tegafur + uracil) has been developed to enhance the efficacy of tegafur....
Prognostic Effect of Vascular Endothelial Growth Factor and Angiogenesis in Gastric Carcinoma

Kim MI, Kim SY, Lee JJ, Yoon HJ, Kim YW, Cho KS

  • Cancer Res Treat.
  • 2003 Jun;35(3):218-223.
PURPOSE: Many studies have shown that angiogenesis has an important role in the growth, progression, and metastasis of solid tumors. Recently, several angiogenic factors have been identified. Vascular endothelial growth...
Gemcitabine and Infusional 5-Fluorouracil in Advanced Pancreatic Cancer: A Clinical Benefit Response-Oriented Phase II Study

Choi JH, Ahn MJ, Im SA, Kim BS, Oh HS, Lee HW, Mun YC, Seong CM, Lee SN, Lee YY, Choi IY, Kim IS

  • Cancer Res Treat.
  • 2003 Jun;35(3):213-217.
PURPOSE: Gemcitabine and 5-fluorouracil (5-FU) are two compounds with reproducible activity against advanced pancreatic carcinomas. To evaluate the activity and feasibility of this combination chemotherapy, a multi-institutional phase II study...
Invasion-Metastasis by Hepatocyte Growth Factor/c-Met Signaling Concomitant with Induction of Urokinase Plasminogen Activator in Human Pancreatic Cancer: Role as Therapeutic Target

Lee KH, Hyun MS, Kim JR

  • Cancer Res Treat.
  • 2003 Jun;35(3):207-212.
PURPOSE: Increased expression of the hepatocytes growth factor (HGF) receptor (c-Met) and urokinase type plasminogen activator (uPA) correlate with the development and metastasis of cancers. However, the mechanisms by which...
Development of a Conditional Replication Competent Adenovirus, Controlled by the Human Telomerase Promoter (hTERT)

Kim E, Kim JH, Shin HY, Lee HS, Sohn JH, Yang JM, Kim J, Yun CO

  • Cancer Res Treat.
  • 2003 Jun;35(3):191-206.
PURPOSE: This study has been planned to generate a replication-competent adenovirus which replicates in a cancer cell-specific manner, thus minimizing the side effects and toxicity of cancer gene therapy. MATERIALS...
Cell-Specific Growth Inhibition of Human Cervical Cancer Cell by Recombinant Adenovirus p53 in vitro and in vivo

Bae SM, Kim YW, Yoon JH, Yoo JY, Seo YS, Nam SL, Lee JM, Namkoong S, Kim CK, Kim YW, Ahn WS

  • Cancer Res Treat.
  • 2003 Jun;35(3):181-190.
PURPOSE: Despite the significance of the p53 adenoviral vector in cancer gene therapy, an advanced strategy for the development of preferential tumor cell-specific delivery and the long-term persistent gene expression...
Treatment of Small Cell Lung Cancer

Horiike A, Saijo N

  • Cancer Res Treat.
  • 2003 Jun;35(3):177-180.
Among patients with lung cancer, approximately 15% have small cell lung cancer (SCLC), SCLC is usually staged as either limited and extensive. Extensive-stage SCLC is treated primarily with chemotherapy. A...
Cancer Gene Therapy: Limitations and Progress

Heo DS

  • Cancer Res Treat.
  • 2003 Jun;35(3):175-176.
No abstract available.

Go to Top

Copyright © 2020 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: